1. Home
  2. ZVRA vs HQL Comparison

ZVRA vs HQL Comparison

Compare ZVRA & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

N/A

Current Price

$12.01

Market Cap

664.7M

Sector

Health Care

ML Signal

N/A

Logo abrdn Life Sciences Investors Shares of Beneficial Interest

HQL

abrdn Life Sciences Investors Shares of Beneficial Interest

N/A

Current Price

$18.64

Market Cap

539.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ZVRA
HQL
Founded
2006
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
664.7M
539.1M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
ZVRA
HQL
Price
$12.01
$18.64
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
★ $25.25
N/A
AVG Volume (30 Days)
★ 815.8K
109.8K
Earning Date
11-03-2026
01-01-0001
Dividend Yield
N/A
★ 11.56%
EPS Growth
★ 159.21
N/A
EPS
★ 1.03
0.79
Revenue
★ $106,470,000.00
N/A
Revenue This Year
$43.42
N/A
Revenue Next Year
$16.20
N/A
P/E Ratio
★ $11.25
$22.73
Revenue Growth
★ 350.91
N/A
52 Week Low
$8.01
$15.66
52 Week High
$15.04
$22.67

Technical Indicators

Market Signals
Indicator
ZVRA
HQL
Relative Strength Index (RSI) 63.37 54.67
Support Level $9.58 $16.78
Resistance Level $12.19 $19.00
Average True Range (ATR) 0.54 0.55
MACD 0.23 0.11
Stochastic Oscillator 93.43 78.24

Price Performance

Historical Comparison
ZVRA
HQL

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

About HQL abrdn Life Sciences Investors Shares of Beneficial Interest

abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.

Share on Social Networks: